{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:36:33Z","timestamp":1788456993689,"version":"build-2803163510"},"reference-count":277,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jceh.2019.09.007","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T01:40:23Z","timestamp":1569202823000},"page":"43-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["2019 Update of Indian National Association for Study of the Liver\u00a0Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6680-7227","authenticated-orcid":false,"given":"Ashish","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrat K.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaram P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-494X","authenticated-orcid":false,"given":"Rakesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil C.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Bhangui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh K.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Datta Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod K.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-2664","authenticated-orcid":false,"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6775-0776","authenticated-orcid":false,"given":"Premashish","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-8334","authenticated-orcid":false,"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.G.","family":"Mohan Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8905-5889","authenticated-orcid":false,"given":"Amar","family":"Mukund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0005-2508","authenticated-orcid":false,"given":"Aabha","family":"Nagral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanjan","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi B.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padaki N.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek A.","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1247-437X","authenticated-orcid":false,"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-6969","authenticated-orcid":false,"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Wadhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/j.jceh.2019.09.007_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jceh.2014.04.003","article-title":"The Indian national association for study of the liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the Puri recommendations","volume":"4","author":"Kumar","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib2","unstructured":"Three year report of PBCR 2012-2014. http:\/\/ncdirindia.org\/NCRP\/ALL_NCRP_REPORTS\/PBCR_REPORT_2012_2014\/ALL_CONTENT\/Printed_Version.htm. Accessed August 12, 2018."},{"key":"10.1016\/j.jceh.2019.09.007_bib3","first-page":"748","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jceh.2019.09.007_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib6","doi-asserted-by":"crossref","first-page":"511.e1","DOI":"10.1016\/j.medcli.2016.01.028","article-title":"Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH","volume":"146","author":"Forner","year":"2016","journal-title":"Med Clin (Barc)."},{"issue":"suppl 1","key":"10.1016\/j.jceh.2019.09.007_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1590\/s0004-28032015000500001","article-title":"Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma","volume":"52","author":"Carrilho","year":"2015","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3348\/kjr.2015.16.3.465","article-title":"2014 Korean liver cancer study group-national cancer center Korea practice guideline for the management of hepatocellular carcinoma","volume":"16","year":"2015","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib9","first-page":"267","article-title":"2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma","volume":"9","year":"2015","journal-title":"Gut Liver"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2019.09.007_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000368141","article-title":"Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update","volume":"87","author":"Kudo","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.jceh.2019.09.007_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib12","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2019.09.007_bib13","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib14","first-page":"274","article-title":"Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India","volume":"26","author":"Paul","year":"2007","journal-title":"Indian J Gastroenterol Off J Indian Soc Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/COH.0000000000000335","article-title":"Hepatocellular carcinoma in patients with HIV","volume":"12","author":"Dika","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"issue":"suppl ment","key":"10.1016\/j.jceh.2019.09.007_bib16","first-page":"C284","article-title":"Association between hepatitis B virus\/hepatitis C virus infection and primary hepatocellular carcinoma risk: a meta-analysis based on Chinese population","volume":"12","author":"Li","year":"2016","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.jceh.2019.09.007_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.510260308","article-title":"Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study","volume":"26","author":"Donato","year":"1997","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib18","first-page":"459","article-title":"Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients","volume":"6","author":"Ohki","year":"2008","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jceh.2019.09.007_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10620-015-3983-3","article-title":"Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review","volume":"61","author":"Dyal","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2019.09.007_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1615\/JEnvironPatholToxicolOncol.2013007166","article-title":"A\u00a0review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses","volume":"32","author":"Moudgil","year":"2013","journal-title":"J\u00a0Environ Pathol Toxicol Oncol Off Organ Int Soc Environ Toxicol Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.clinbiochem.2011.07.017","article-title":"Role of aflatoxin B1 as a risk for primary liver cancer in north Indian population","volume":"44","author":"Asim","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jceh.2019.09.007_bib22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1440-1746.2007.04908.x","article-title":"Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India","volume":"22","author":"Kumar","year":"2007","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000231886","article-title":"Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India","volume":"77","author":"Paul","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.jceh.2019.09.007_bib24","first-page":"25","article-title":"Hepatocellular carcinoma continues to be diagnosed in the advanced stage: profile of hepatocellular carcinoma in a tertiary care hospital in South India","volume":"43","author":"Pal","year":"2013","journal-title":"Trop Dr"},{"key":"10.1016\/j.jceh.2019.09.007_bib25","first-page":"172","article-title":"Viral genotypes and associated risk factors of hepatocellular carcinoma in India","volume":"9","author":"Sarma","year":"2012","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jceh.2013.08.007","article-title":"Hepatitis B virus infection can cause hepatocellular carcinoma in less advanced liver cirrhosis: a comparative study of 142 patients from north India","volume":"3","author":"Arora","year":"2013","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12029-010-9222-4","article-title":"Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes","volume":"42","author":"Vivekanandan","year":"2011","journal-title":"J\u00a0Gastrointest Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/jmv.21774","article-title":"Hepatitis B virus BCP, Precore\/core, X gene mutations\/genotypes and the risk of hepatocellular carcinoma in India","volume":"82","author":"Asim","year":"2010","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jceh.2019.09.007_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005609","article-title":"Three polymorphisms of tumor necrosis factor-alpha and hepatitis B virus related hepatocellular carcinoma: a meta-analysis","volume":"95","author":"Xiao","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2019.09.007_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.29115","article-title":"Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort","volume":"66","author":"Bruden","year":"2017","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib32","doi-asserted-by":"crossref","first-page":"W610","DOI":"10.2214\/AJR.12.9151","article-title":"Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis","volume":"200","author":"Lewis","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"2 suppl l","key":"10.1016\/j.jceh.2019.09.007_bib33","first-page":"61","article-title":"Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma","volume":"24","author":"Caselmann","year":"1996","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/jmv.23290","article-title":"Hepatitis C virus related hepatocellular carcinoma: a case control study from India","volume":"84","author":"Sarma","year":"2012","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jceh.2019.09.007_bib35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jhep.2016.06.009","article-title":"Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment","volume":"65","author":"Kozbial","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib36","first-page":"1157","article-title":"A\u00a0meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma","volume":"37","author":"Cabibbo","year":"2017","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jceh.2019.09.007_bib37","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib38","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3748\/wjg.v24.i24.2582","article-title":"Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows","volume":"24","author":"Guarino","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2016.02.012","article-title":"Alcoholic liver disease: high risk or low risk for developing hepatocellular carcinoma?","volume":"20","author":"Joshi","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2019.09.007_bib40","first-page":"369","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jceh.2019.09.007_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","article-title":"Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: a follow-up study in Taiwan","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2019.09.007_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.23736\/S0026-4806.16.04601-2","article-title":"The effect of prediabetes on hepatocellular carcinoma risk: a systematic review and meta-analysis","volume":"108","author":"Xu","year":"2017","journal-title":"Minerva Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib43","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib44","first-page":"1342","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jceh.2019.09.007_bib45","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hep.1840360609","article-title":"NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States","volume":"36","author":"Marrero","year":"2002","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib46","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/hep.23838","article-title":"Nonalcoholic fatty liver in a developing country is responsible for significant liver disease","volume":"52","author":"Duseja","year":"2010","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12664-017-0785-x","article-title":"Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India","volume":"36","author":"David","year":"2017","journal-title":"Indian J Gastroenterol Off J Indian Soc Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib48","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s00535-009-0112-0","article-title":"Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis","volume":"44","author":"Kawada","year":"2009","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.21037\/hbsn.2017.07.07","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history","volume":"6","author":"Issa","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jceh.2019.09.007_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib51","first-page":"1207","article-title":"Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis","volume":"15","author":"Tansel","year":"2017","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jceh.2019.09.007_bib52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.23736\/S0026-4806.16.04764-9","article-title":"miR-146a rs2910164 and hepatocellular carcinoma: a meta-analysis","volume":"108","author":"Dong","year":"2017","journal-title":"Minerva Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcma.2016.09.009","article-title":"Study of the association between five polymorphisms and risk of hepatocellular carcinoma: a meta-analysis","volume":"80","author":"Yu","year":"2017","journal-title":"J\u00a0Chin Med Assoc JCMA"},{"key":"10.1016\/j.jceh.2019.09.007_bib54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.23736\/S0026-4806.16.04571-7","article-title":"Association of HLA-DRB1 gene polymorphisms with hepatocellular carcinoma risk: a meta-analysis","volume":"108","author":"Liu","year":"2017","journal-title":"Minerva Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib55","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jcmm.12896","article-title":"The association of six non-synonymous variants in three DNA repair genes with hepatocellular carcinoma risk: a meta-analysis","volume":"20","author":"Shi","year":"2016","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib56","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1155\/2010\/328408","article-title":"Genetic polymorphism of glutathione S transferases M1 and T1 in Indian patients with hepatocellular carcinoma","volume":"28","author":"Asim","year":"2010","journal-title":"Dis Markers"},{"key":"10.1016\/j.jceh.2019.09.007_bib57","first-page":"A.3P.1","article-title":"Universal precautions: necessary safety procedures when handling human blood, body fluids, and specimens","volume":"118","author":"Bierer","year":"2017","journal-title":"Curr Protoc Im"},{"key":"10.1016\/j.jceh.2019.09.007_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0255-0857.115623","article-title":"Universal screening versus universal precautions in the context of preoperative screening for HIV, HBV, HCV in India","volume":"31","author":"Ahmed","year":"2013","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib59","first-page":"369","article-title":"Hepatitis B vaccines: WHO position paper\u2014July 2017","volume":"92","year":"2017","journal-title":"Releve Epidemiol Hebd"},{"key":"10.1016\/j.jceh.2019.09.007_bib60","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib61","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.3748\/wjg.v19.i47.8822","article-title":"Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy","volume":"19","author":"Vlachogiannakos","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12876-017-0606-9","article-title":"Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis","volume":"17","author":"Bang","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2015.08.028","article-title":"Hepatocellular carcinoma and lifestyles","volume":"64","author":"Saran","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib64","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s10620-016-4085-6","article-title":"Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD","volume":"61","author":"Reeves","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jceh.2019.09.007_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9100130","article-title":"Alcohol and hepatocellular carcinoma: adding fuel to the flame","volume":"9","author":"Ramadori","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.jceh.2019.09.007_bib66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2217\/hep.15.40","article-title":"Role of alcohol in the development and progression of hepatocellular carcinoma","volume":"3","author":"McKillop","year":"2016","journal-title":"Hepatic Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib67","first-page":"1","article-title":"Lyon, 13-20 October 1987","volume":"44","year":"1988","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"10.1016\/j.jceh.2019.09.007_bib68","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","article-title":"Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project","volume":"118","author":"Petrick","year":"2018","journal-title":"Br J Canc"},{"key":"10.1016\/j.jceh.2019.09.007_bib69","doi-asserted-by":"crossref","first-page":"15943","DOI":"10.3748\/wjg.v20.i43.15943","article-title":"Alcohol and hepatocellular carcinoma: a review and a point of view","volume":"20","author":"Testino","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib70","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/1471-2407-11-446","article-title":"How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature","volume":"11","author":"Heckley","year":"2011","journal-title":"BMC Canc"},{"key":"10.1016\/j.jceh.2019.09.007_bib71","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2019.09.007_bib73","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.surg.2017.09.026","article-title":"Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection","volume":"163","author":"Nishio","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.jceh.2019.09.007_bib74","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007435","article-title":"Statins intake and risk of liver cancer: a dose-response meta analysis of prospective cohort studies","volume":"96","author":"Yi","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2019.09.007_bib75","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CEJ.0000000000000252","article-title":"Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies","volume":"26","author":"Bravi","year":"2017","journal-title":"Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP"},{"key":"10.1016\/j.jceh.2019.09.007_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013739","article-title":"Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis","volume":"7","author":"Kennedy","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jceh.2019.09.007_bib77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/01635581.2017.1263754","article-title":"Green tea consumption and the risk of liver cancer: a meta-analysis","volume":"69","author":"Ni","year":"2017","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-062613-093128","article-title":"Metformin in cancer treatment and prevention","volume":"66","author":"Morales","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib79","article-title":"Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2019.09.007_bib80","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bpg.2016.10.006","article-title":"Surveillance for hepatocellular carcinoma","volume":"30","author":"D\u00edaz-Gonz\u00e1lez","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"suppl 3","key":"10.1016\/j.jceh.2019.09.007_bib81","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jceh.2014.03.044","article-title":"Role of surveillance in prevention of hepatocellular carcinoma","volume":"4","author":"Panda","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib82","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2019.09.007_bib83","first-page":"1","article-title":"Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis","author":"Caviglia","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib84","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2016.10.042","article-title":"Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma","volume":"152","author":"Singal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2019.09.007_bib85","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejrad.2018.01.025","article-title":"Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines","volume":"101","author":"Ayuso","year":"2018","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jmri.25345","article-title":"Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"45","author":"Duncan","year":"2017","journal-title":"J\u00a0Magn Reson Imag JMRI"},{"key":"10.1016\/j.jceh.2019.09.007_bib87","article-title":"Assessing diagnostic value of contrast-enhanced ultrasound and contrast-enhanced computed tomography in detecting small hepatocellular carcinoma: a meta-analysis","volume":"96","author":"Huang","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"suppl ment","key":"10.1016\/j.jceh.2019.09.007_bib88","first-page":"C274","article-title":"A\u00a0meta-analysis of contrast-enhanced ultrasound for small hepatocellular carcinoma diagnosis","volume":"12","author":"Deng","year":"2016","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.jceh.2019.09.007_bib89","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/JHC.S159808","article-title":"Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist","volume":"5","author":"Quaglia","year":"2018","journal-title":"J\u00a0Hepatocell Carcinoma"},{"key":"10.1016\/j.jceh.2019.09.007_bib90","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.3748\/wjg.v24.i35.4000","article-title":"Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma","volume":"24","author":"Rastogi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib91","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E","article-title":"Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies","volume":"7","author":"Edmondson","year":"1954","journal-title":"Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmed.2017.00193","article-title":"Histological grading of hepatocellular carcinoma-A systematic review of literature","volume":"4","author":"Martins-Filho","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib93","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4254\/wjh.v10.i7.452","article-title":"Contemporary role of liver biopsy in hepatocellular carcinoma","volume":"10","author":"Sparchez","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib94","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/gut.2008.149062","article-title":"Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis","volume":"57","author":"Silva","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2019.09.007_bib95","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/hep.15.6","article-title":"The emerging role of positron emission tomography in hepatocellular carcinoma","volume":"2","author":"Dubash","year":"2015","journal-title":"Hepatic Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib96","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011970","article-title":"18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual\/recurrent hepatocellular carcinoma","volume":"97","author":"Liao","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2019.09.007_bib97","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.116.182022","article-title":"18F-FDG PET\/CT can predict survival of advanced hepatocellular carcinoma patients: a multicenter retrospective cohort study","volume":"58","author":"Na","year":"2017","journal-title":"J\u00a0Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib98","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4251\/wjgo.v10.i10.336","article-title":"Role of pre-transplant 18F-FDG PET\/CT in predicting hepatocellular carcinoma recurrence after liver transplantation","volume":"10","author":"Yaprak","year":"2018","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1089-3261(05)70158-6","article-title":"The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma","volume":"5","author":"Johnson","year":"2001","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2019.09.007_bib100","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z","article-title":"Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients","volume":"64","author":"Nomura","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib101","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2012.05060.x","article-title":"Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma","volume":"35","author":"Hakeem","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2019.09.007_bib102","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig Dis Basel Switz"},{"key":"10.1016\/j.jceh.2019.09.007_bib103","doi-asserted-by":"crossref","DOI":"10.1007\/s13277-016-5443-x","article-title":"Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma","author":"Xing","year":"2016","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib104","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1159\/000485396","article-title":"Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review","volume":"44","author":"Zheng","year":"2017","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"10.1016\/j.jceh.2019.09.007_bib105","doi-asserted-by":"crossref","first-page":"22854","DOI":"10.18632\/oncotarget.15281","article-title":"Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib106","doi-asserted-by":"crossref","first-page":"81830","DOI":"10.18632\/oncotarget.13244","article-title":"Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma","volume":"7","author":"Song","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib107","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007496","article-title":"Diagnostic value of long noncoding RNAs for hepatocellular carcinoma: a PRISMA-compliant meta-analysis","volume":"96","author":"Hao","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2019.09.007_bib108","first-page":"961","article-title":"Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"19","author":"Zheng","year":"2017","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"issue":"suppl 3","key":"10.1016\/j.jceh.2019.09.007_bib109","first-page":"S235","article-title":"Molecular classification of hepatocellular carcinoma","volume":"42","author":"Zucman-Rossi","year":"2010","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.jceh.2019.09.007_bib110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000445275","article-title":"Treatment of hepatocellular carcinoma","volume":"34","author":"D\u00edaz-Gonz\u00e1lez","year":"2016","journal-title":"Dig Dis Basel Switz"},{"key":"10.1016\/j.jceh.2019.09.007_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186930","article-title":"Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma: a systemic review and meta-analysis","volume":"12","author":"Tan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.09.007_bib112","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s11605-017-3410-5","article-title":"Anterior approach to improve the prognosis in HCC patients via decreasing dissemination of EpCAM+ circulating tumor cells","volume":"21","author":"Hao","year":"2017","journal-title":"J\u00a0Gastrointest Surg Off J Soc Surg Aliment Tract"},{"key":"10.1016\/j.jceh.2019.09.007_bib113","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/jso.24433","article-title":"Anterior approach to improve the long-term outcome in patients with large-size hepatocellular carcinoma having liver resection","volume":"114","author":"Hao","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib114","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.3748\/wjg.v20.i25.8274","article-title":"Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis","volume":"20","author":"Twaij","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib115","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1007\/s00464-014-4041-5","article-title":"Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma","volume":"29","author":"Li","year":"2015","journal-title":"Surg Endosc"},{"key":"10.1016\/j.jceh.2019.09.007_bib116","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008043","article-title":"Prognostic impact of surgical margin in patients with hepatocellular carcinoma: a meta-analysis","volume":"96","author":"Zhong","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2019.09.007_bib117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-230X-9-31","article-title":"Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma","volume":"9","author":"Bouza","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib118","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12957-015-0516-7","article-title":"Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials","volume":"13","author":"Yang","year":"2015","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib119","first-page":"381","article-title":"Radiofrequency ablation with or without ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"107","author":"Zhu","year":"2016","journal-title":"Minerva Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/02656736.2015.1127434","article-title":"Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"32","author":"Facciorusso","year":"2016","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"10.1016\/j.jceh.2019.09.007_bib121","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s00270-019-02164-2","article-title":"Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience","volume":"42","author":"Kalra","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib122","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib123","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/hep-2016-0010","article-title":"When to consider liver transplantation in hepatocellular carcinoma patients?","volume":"4","author":"Ma","year":"2017","journal-title":"Hepatic Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib124","first-page":"341","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal","volume":"42","author":"Trevisani","year":"2010","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.jceh.2019.09.007_bib125","first-page":"322","article-title":"Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature","volume":"53","author":"Sotiropoulos","year":"2006","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.jceh.2019.09.007_bib126","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.suronc.2014.11.001","article-title":"Outcomes of hepatectomy for noncirrhotic hepatocellular carcinoma: a systematic review","volume":"23","author":"Zhou","year":"2014","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib127","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/bjs.10677","article-title":"Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma","volume":"104","author":"Ng","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.jceh.2019.09.007_bib128","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.crad.2017.07.024","article-title":"Radiofrequency ablation versus resection for hepatocellular carcinoma in patients with Child-Pugh A liver cirrhosis: a meta-analysis","volume":"72","author":"Jia","year":"2017","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib129","first-page":"CD011650","article-title":"Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis","volume":"3","author":"Majumdar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jceh.2019.09.007_bib130","first-page":"836","article-title":"Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: an attempt to perform an ideal meta-analysis","volume":"23","author":"Menahem","year":"2017","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"10.1016\/j.jceh.2019.09.007_bib131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jss.2016.11.002","article-title":"Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis","volume":"210","author":"Zhang","year":"2017","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jceh.2019.09.007_bib132","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/000313481808400238","article-title":"Comparison of transarterial chemoembolization combined with radiofrequency ablation therapy versus surgical resection for early hepatocellular carcinoma","volume":"84","author":"Yi","year":"2018","journal-title":"Am Surg"},{"key":"10.1016\/j.jceh.2019.09.007_bib133","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib134","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00365521.2016.1236396","article-title":"Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"52","author":"Huang","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib135","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/jgh.13727","article-title":"Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: a meta-analysis","volume":"32","author":"Si","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib136","doi-asserted-by":"crossref","first-page":"109723","DOI":"10.18632\/oncotarget.21299","article-title":"Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis","volume":"8","author":"Shang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib137","first-page":"1525","article-title":"Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2017","journal-title":"J\u00a0BUON Off J Balk Union Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib138","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13246","article-title":"No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant","volume":"32","author":"Satapathy","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jceh.2019.09.007_bib139","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-015-1373-z","article-title":"Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial","volume":"15","author":"Hoffmann","year":"2015","journal-title":"BMC Canc"},{"key":"10.1016\/j.jceh.2019.09.007_bib140","first-page":"593","article-title":"[Hepatic, arterial embolization in patients with malignant liver tumours (author's transl)]","volume":"17","author":"Doyon","year":"1974","journal-title":"Ann Radiol (Paris)"},{"key":"10.1016\/j.jceh.2019.09.007_bib141","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/1097-0142(19831215)52:12<2193::AID-CNCR2820521203>3.0.CO;2-R","article-title":"Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer","volume":"52","author":"Nakakuma","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib142","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0038-1673423","article-title":"Treatment of liver tumors with transarterial chemoembolization","volume":"35","author":"Poliektov","year":"2018","journal-title":"Semin Interv Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib143","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.18632\/oncotarget.13813","article-title":"Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib144","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib146","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jceh.2019.09.007_bib147","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clinre.2016.05.013","article-title":"Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"41","author":"Chen","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib148","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jvir.2016.11.037","article-title":"The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Pung","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol JVIR"},{"key":"10.1016\/j.jceh.2019.09.007_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184597","article-title":"Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials","volume":"12","author":"Katsanos","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.09.007_bib150","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.hpb.2017.03.009","article-title":"Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma","volume":"19","author":"Stevens","year":"2017","journal-title":"HPB"},{"key":"10.1016\/j.jceh.2019.09.007_bib151","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.18632\/oncotarget.12348","article-title":"A\u00a0mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients","volume":"8","author":"Tao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib152","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/jjco\/hyy138","article-title":"Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis","volume":"48","author":"Jin","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib153","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","article-title":"Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis","volume":"39","author":"Lobo","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib154","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4103\/1319-3767.191139","article-title":"A\u00a0systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"22","author":"Jia","year":"2016","journal-title":"Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc"},{"key":"10.1016\/j.jceh.2019.09.007_bib155","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib156","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00330-016-4548-3","article-title":"Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma","volume":"27","author":"Ludwig","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib157","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2019.09.007_bib158","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.29126","article-title":"The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial","volume":"136","author":"Chao","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib159","article-title":"Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: a post hoc analysis of the START trial","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jceh.2019.09.007_bib160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.clinre.2016.04.006","article-title":"Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Zeng","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib161","first-page":"CD011649","article-title":"Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis","volume":"3","author":"Roccarina","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jceh.2019.09.007_bib162","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/hep.29668","article-title":"Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice","volume":"67","author":"Giannini","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib163","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4166\/kjg.2019.73.1.10","article-title":"New systemic therapies for advanced hepatocellular carcinoma","volume":"73","author":"Kim","year":"2019","journal-title":"Korean J Gastroenterol Taehan Sohwagi Hakhoe Chi"},{"key":"10.1016\/j.jceh.2019.09.007_bib164","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib166","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.29486","article-title":"Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis","volume":"67","author":"Finn","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib167","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/17474124.2017.1264874","article-title":"Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival","volume":"11","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib168","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.15088","article-title":"Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib","volume":"49","author":"D\u00edaz-Gonz\u00e1lez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2019.09.007_bib169","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib171","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jceh.2019.09.007_bib172","doi-asserted-by":"crossref","DOI":"10.1007\/s00535-019-01554-0","article-title":"Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan","author":"Kobayashi","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib173","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jceh.2019.09.007_bib174","first-page":"311","article-title":"New systemic treatments in advanced hepatocellular carcinoma","volume":"25","author":"Sanduzzi-Zamparelli","year":"2019","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"10.1016\/j.jceh.2019.09.007_bib175","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib176","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/annonc\/mdw651","article-title":"Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study","volume":"28","author":"Kelley","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib177","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib178","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib179","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00535-016-1247-4","article-title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial","volume":"52","author":"Kudo","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib180","first-page":"17","article-title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study","volume":"81","author":"Chau","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.jceh.2019.09.007_bib181","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib182","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-019-00624-w","article-title":"The changing landscape of systemic treatment of advanced hepatocellular carcinoma: new targeted agents and immunotherapies","author":"Marquardt","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib183","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jceh.2019.09.007_bib184","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A\u00a0clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib185","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib186","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib187","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/jcp.27324","article-title":"Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"234","author":"Wang","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib188","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib189","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB"},{"key":"10.1016\/j.jceh.2019.09.007_bib190","doi-asserted-by":"crossref","first-page":"29416","DOI":"10.18632\/oncotarget.15075","article-title":"Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib191","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.21873\/anticanres.11211","article-title":"Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a western randomized controlled trial","volume":"36","author":"Giorgio","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jceh.2019.09.007_bib192","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188031","article-title":"Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: a nomogram study","volume":"12","author":"Hsu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.09.007_bib193","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"Giannini","year":"2015","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib194","doi-asserted-by":"crossref","first-page":"454","DOI":"10.6061\/clinics\/2017(08)01","article-title":"Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage","volume":"72","author":"Kikuchi","year":"2017","journal-title":"Clin Sao Paulo Braz"},{"key":"10.1016\/j.jceh.2019.09.007_bib195","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(11)70144-9","article-title":"Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study","volume":"12","author":"Vitale","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib196","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1245\/s10434-011-1551-4","article-title":"Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages","volume":"18","author":"D'Avola","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"suppl 3","key":"10.1016\/j.jceh.2019.09.007_bib197","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jceh.2014.03.049","article-title":"Role of supportive care for terminal stage hepatocellular carcinoma","volume":"4","author":"Kumar","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib198","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.semradonc.2018.06.005","article-title":"Radiotherapy for hepatocellular carcinoma","volume":"28","author":"Yu","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib199","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00066-013-0450-y","article-title":"Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer","volume":"190","author":"Guckenberger","year":"2014","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"10.1016\/j.jceh.2019.09.007_bib200","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1002\/cam4.893","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis","volume":"5","author":"Seo","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jceh.2019.09.007_bib201","first-page":"CD011314","article-title":"External beam radiotherapy for unresectable hepatocellular carcinoma","volume":"3","author":"Abdel-Rahman","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jceh.2019.09.007_bib202","first-page":"90","article-title":"Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area","volume":"37","author":"Im","year":"2017","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.jceh.2019.09.007_bib203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-230X-14-84","article-title":"Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis","volume":"14","author":"Nakazawa","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib204","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.2147\/OTT.S156844","article-title":"Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population","volume":"11","author":"Ni","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.jceh.2019.09.007_bib205","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/annonc\/mdw323","article-title":"Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial","volume":"27","author":"Ikeda","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib206","first-page":"1379","article-title":"Improved chemotherapy for hepatocellular carcinoma","volume":"32","author":"Cao","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jceh.2019.09.007_bib207","first-page":"360","article-title":"Systemic chemotherapy for advanced hepatocellular carcinoma: past, present, and future","volume":"3","author":"Ikeda","year":"2015","journal-title":"Dis Basel Switz"},{"key":"10.1016\/j.jceh.2019.09.007_bib208","doi-asserted-by":"crossref","first-page":"44976","DOI":"10.18632\/oncotarget.16689","article-title":"Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib209","first-page":"2043","article-title":"Thalidomide combined with transcatheter arterial chemoembolization (TACE) for intermediate or advanced hepatocellular carcinoma: a systematic review and grade Approach","volume":"19","author":"Yang","year":"2018","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"10.1016\/j.jceh.2019.09.007_bib210","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/jgh.13789","article-title":"Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: a meta-analysis","volume":"32","author":"Lv","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jgh.13529","article-title":"Arsenic trioxide intravenous infusion combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with pulmonary metastasis: long-term outcome analysis","volume":"32","author":"Hu","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib212","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jceh.2019.09.007_bib213","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174222","article-title":"Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy","volume":"12","author":"Mo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.09.007_bib214","first-page":"1275","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis","volume":"48","author":"Wang","year":"2016","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.jceh.2019.09.007_bib215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168798","article-title":"Is adjuvant cellular immunotherapy essential after TACE-predominant minimally-invasive treatment for hepatocellular carcinoma? A systematic meta-analysis of studies including 1774 patients","volume":"11","author":"Ding","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.09.007_bib216","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jcyt.2016.09.002","article-title":"Cytokine-induced killer cell infusion combined with conventional treatments produced better prognosis for hepatocellular carcinoma patients with barcelona clinic liver cancer B or earlier stage: a systematic review and meta-analysis","volume":"18","author":"Li","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jceh.2019.09.007_bib217","doi-asserted-by":"crossref","first-page":"31318","DOI":"10.18632\/oncotarget.15454","article-title":"Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib218","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.intimp.2016.09.015","article-title":"TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis","volume":"40","author":"He","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jceh.2019.09.007_bib219","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2147\/DDDT.S124399","article-title":"Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jceh.2019.09.007_bib220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133488","article-title":"Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis","volume":"10","author":"Vincenzi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.09.007_bib221","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/hep-2017-0018","article-title":"Radiologic criteria of response to systemic treatments for hepatocellular carcinoma","volume":"4","author":"Tovoli","year":"2017","journal-title":"Hepatic Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib222","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib223","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.jceh.2019.09.007_bib224","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jceh.2014.05.005","article-title":"Treatment response evaluation and follow-up in hepatocellular carcinoma","volume":"4","author":"Arora","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib225","doi-asserted-by":"crossref","first-page":"48586","DOI":"10.18632\/oncotarget.9374","article-title":"Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib226","first-page":"732","article-title":"Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases","volume":"15","author":"Chen","year":"2013","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"10.1016\/j.jceh.2019.09.007_bib227","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.18632\/oncotarget.14858","article-title":"High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jceh.2019.09.007_bib228","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jso.24869","article-title":"Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review","volume":"117","author":"Moris","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib229","article-title":"Rupture of hepatocellular carcinoma: a tale of 20 cases from a tertiary care center in northern India","author":"Sahu","year":"2018","journal-title":"J\u00a0Gastrointest Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib230","article-title":"Systematic review of treatment strategy for recurrent hepatocellular carcinoma: salvage liver transplantation or curative locoregional therapy","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"Pt A","key":"10.1016\/j.jceh.2019.09.007_bib231","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijsu.2018.04.041","article-title":"The surgical challenges of salvage living donor liver transplantation for Hepatocellular carcinoma; the cumulative experience of 100 cases - a retrospective cohort study and a propensity score analysis","volume":"54","author":"Yong","year":"2018","journal-title":"Int J Surg Lond Engl"},{"key":"10.1016\/j.jceh.2019.09.007_bib232","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1097\/TP.0000000000001730","article-title":"Locoregional therapy with curative intent versus primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis","volume":"101","author":"Murali","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jceh.2019.09.007_bib233","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1016\/j.transproceed.2016.09.047","article-title":"Harm and benefits of salvage transplantation for hepatocellular carcinoma: an updated meta-analysis","volume":"48","author":"Xiong","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jceh.2019.09.007_bib234","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/bjs.10597","article-title":"Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma","volume":"104","author":"Erridge","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.jceh.2019.09.007_bib235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hpb.2016.10.003","article-title":"Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis","volume":"19","author":"Gavriilidis","year":"2017","journal-title":"HPB"},{"key":"10.1016\/j.jceh.2019.09.007_bib236","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/hep.14.22","article-title":"Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma","volume":"1","author":"Ganne-Carri\u00e9","year":"2014","journal-title":"Hepatic Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib237","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/hepr.12705","article-title":"Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation","volume":"47","author":"Ikemoto","year":"2017","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib238","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","article-title":"Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review","volume":"21","author":"de'Angelis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib239","first-page":"3421","article-title":"Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation","volume":"21","author":"Guerrini","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jceh.2019.09.007_bib240","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2217\/fon.15.239","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: an update","volume":"11","author":"Mazzola","year":"2015","journal-title":"Future Oncol Lond Engl"},{"key":"10.1016\/j.jceh.2019.09.007_bib241","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4254\/wjh.v7.i8.1142","article-title":"Management of recurrent hepatocellular carcinoma after liver transplant","volume":"7","author":"Chok","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib242","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ijc.30521","article-title":"Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"140","author":"Manthravadi","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib243","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib244","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/hepr.12584","article-title":"Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis","volume":"46","author":"Liu","year":"2016","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib245","doi-asserted-by":"crossref","first-page":"7075935","DOI":"10.1155\/2017\/7075935","article-title":"Efficacy of nucleot(s)ide analogs therapy in patients with unresectable HBV-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"2017","author":"He","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.jceh.2019.09.007_bib246","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/jvh.12855","article-title":"Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals","volume":"25","author":"Cho","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2019.09.007_bib247","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122041","article-title":"Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma","volume":"10","author":"Jang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2019.09.007_bib248","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jceh.2018.06.010","article-title":"INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids","volume":"8","author":"Arora","year":"2018","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2019.09.007_bib249","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3748\/wjg.v24.i35.3980","article-title":"Pediatric hepatocellular carcinoma","volume":"24","author":"Khanna","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2019.09.007_bib250","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00268-008-9526-8","article-title":"Malignant liver tumors in South African children: a national audit","volume":"32","author":"Moore","year":"2008","journal-title":"World J Surg"},{"key":"10.1016\/j.jceh.2019.09.007_bib251","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12098-013-1188-3","article-title":"Incidentally detected hepatocellular carcinoma in cirrhotic children","volume":"81","author":"Bhatia","year":"2014","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.jceh.2019.09.007_bib252","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/petr.12754","article-title":"Pediatric hepatocellular carcinoma in a developing country: is the etiology changing?","volume":"20","author":"Palaniappan","year":"2016","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jceh.2019.09.007_bib253","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s13312-016-0941-x","article-title":"Ruptured hepatocellular carcinoma in a child with Budd-Chiari syndrome","volume":"53","author":"Suri","year":"2016","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.jceh.2019.09.007_bib254","first-page":"13","article-title":"Paediatric hepatoblastoma and hepatocellular carcinoma: retrospective study","volume":"8","author":"Chan","year":"2002","journal-title":"Hong Kong Med J Xianggang Yi Xue Za Zhi"},{"key":"10.1016\/j.jceh.2019.09.007_bib255","first-page":"75","article-title":"Hepatitis B virus and cancer prevention. Recent results Cancer Res Fortschritte Krebsforsch Progres","volume":"188","author":"Chang","year":"2011","journal-title":"Dans Rech Sur Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib256","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-200666060-00002","article-title":"Nitisinone in the treatment of hereditary tyrosinaemia type 1","volume":"66","author":"McKiernan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jceh.2019.09.007_bib257","first-page":"982679","article-title":"Two rare cases of hepatocellular carcinoma after Kasai procedure for biliary atresia: a recommendation for close follow-up","volume":"2015","author":"Hirzel","year":"2015","journal-title":"Case Rep Pathol"},{"key":"10.1016\/j.jceh.2019.09.007_bib258","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep.21287","article-title":"Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency","volume":"44","author":"Knisely","year":"2006","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib259","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.mpg.0000179759.60048.c4","article-title":"Hepatocellular carcinoma in children with Alagille syndrome","volume":"41","author":"Bhadri","year":"2005","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2019.09.007_bib260","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10545-005-7500-2","article-title":"Hepatocellular carcinoma in glycogen storage disease type Ia: a case series","volume":"28","author":"Franco","year":"2005","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jceh.2019.09.007_bib261","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/adc.82.6.479","article-title":"Hepatocellular carcinoma in glycogen storage disease type IV","volume":"82","author":"de Moor","year":"2000","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jceh.2019.09.007_bib262","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1615\/CritRevOncog.2013005921","article-title":"Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy","volume":"18","author":"Weinreb","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.jceh.2019.09.007_bib263","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10147-013-0624-8","article-title":"International pediatric liver cancer pathological classification: current trend","volume":"18","author":"Tanaka","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib264","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.21328","article-title":"Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas","volume":"44","author":"Luo","year":"2006","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib265","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mpo.10177","article-title":"Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin","volume":"39","author":"Prokurat","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jceh.2019.09.007_bib266","first-page":"472","article-title":"Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium","volume":"27","author":"L\u00f3pez-Terrada","year":"2014","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.jceh.2019.09.007_bib267","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00247-006-0361-5","article-title":"2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group","volume":"37","author":"Roebuck","year":"2007","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jceh.2019.09.007_bib268","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ctrv.2010.02.013","article-title":"Progress in the surgical treatment of malignant liver tumors in children","volume":"36","author":"Otte","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jceh.2019.09.007_bib269","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/pbc.23295","article-title":"Sorafenib and cisplatin\/doxorubicin (PLADO) in pediatric hepatocellular carcinoma","volume":"58","author":"Schmid","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jceh.2019.09.007_bib270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JHC.S94008","article-title":"Pediatric hepatocellular carcinoma: challenges and solutions","volume":"4","author":"Schmid","year":"2017","journal-title":"J\u00a0Hepatocell Carcinoma"},{"key":"10.1016\/j.jceh.2019.09.007_bib271","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s11605-017-3420-3","article-title":"Hepatocellular carcinoma in children and adolescents: clinical characteristics and treatment","volume":"21","author":"Wang","year":"2017","journal-title":"J\u00a0Gastrointest Surg Off J Soc Surg Aliment Tract"},{"key":"10.1016\/j.jceh.2019.09.007_bib272","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0022-3468(92)90849-3","article-title":"Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival","volume":"27","author":"Tagge","year":"1992","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.jceh.2019.09.007_bib273","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0022-3476(00)44469-0","article-title":"Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence","volume":"136","author":"Reyes","year":"2000","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jceh.2019.09.007_bib274","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MPG.0000000000000431","volume":"59","author":"Squires","year":"2014","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2019.09.007_bib275","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.27191","volume":"60","author":"Squires","year":"2014","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2019.09.007_bib276","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.jpedsurg.2013.05.007","article-title":"Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes","volume":"48","author":"McAteer","year":"2013","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.jceh.2019.09.007_bib277","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jpedsurg.2005.10.091","article-title":"Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database","volume":"41","author":"Austin","year":"2006","journal-title":"J\u00a0Pediatr Surg"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688319302403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688319302403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:05:30Z","timestamp":1760853930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688319302403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":277,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0973688319302403"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2019.09.007","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2019 Update of Indian National Association for Study of the Liver\u00a0Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2019.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Indian National Association for Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}